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Abstract: In the absence of identified therapeutic targets, chemotherapy is the main systemic treatment
option for triple-negative breast cancer (TNBC). The achievement of a pathological complete response
(pCR) after neoadjuvant chemotherapy leads to good outcome, whereas patients not achieving a pCR
are at high risk of relapse. Various trials have evaluated the inclusion of platinum in neoadjuvant
chemotherapy regimens for TNBC, leading to non-univocal results. The panel of the Italian Association
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of Medical Oncology (AIOM) Guidelines on Breast Cancer developed a clinical recommendation
on the addition of platinum to anthracycline/taxane-based neoadjuvant chemotherapy for TNBC
by using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)
methodology and the Evidence to Decision framework (EtD). Five studies were eligible. The panel
identified the following outcomes of benefit: pCR (critical), disease/event-free survival (DFS/EFS,
critical), and overall survival (OS, critical). The panel identified febrile neutropenia (critical), serious
adverse events (critical), anemia grade 3–4 (important), thrombocytopenia grade 3–4 (important) as
outcomes of harms. The probability of pCR was higher in the platinum-based chemotherapy group
versus control group (RR = 1.45, 95%CI 1.28–1.64); however, no impact on long-term outcome was
observed. Neoadjuvant treatment regimens containing platinum resulted in a non-significant increase
in the risk of febrile neutropenia and in a significant increase in the risk serious adverse events,
G3–G4 anemia and G3–G4 thrombocytopenia: 11.3% versus 0.8%, RR = 15.66 (95%CI 6.38–38.44).
The panel judged uncertain/favorable the benefit/harms balance. The panel’s final recommendation
was conditional in favor of the inclusion of platinum in anthracycline/taxane-based neoadjuvant
regimens for TNBC.
Keywords: triple-negative breast cancer; neoadjuvant chemotherapy; platinum; GRADE methodology;
clinical recommendation
1. Introduction
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype, accounting
for around 15% of all diagnoses. Up to one-third of patients diagnosed with TNBC may experience
disease recurrence, with the highest peak within 1–3 years from diagnosis. The pattern of recurrence
often involves visceral sites, leading to high mortality rates and short survival. Triple-negative breast
cancer lacks recognized therapeutic targets; therefore, cytotoxic agents represent the only option of
systemic treatment [1,2].
Despite its aggressiveness, TNBC is highly chemosensitive [3]. This paradox is particularly evident
in the neoadjuvant setting [4]. Indeed, TNBC is associated with higher pathological complete response
(pCR) rates (~30–40%) after neoadjuvant chemotherapy (NACT) as compared to other BC subtypes.
Moreover, the achievement of pCR has the strongest prognostic effect for TNBC as compared to
other subtypes: TNBC patients who achieve a pCR have an excellent survival, on the other hand,
among patients who fail to achieve a pCR, those with TNBC show the highest risk of relapse [4,5].
Neoadjuvant chemotherapy is the standard of care for locally advanced and inflammatory disease
but is also widely used for most of the patients with operable TNBC. Based on the response achieved
after NACT, treatment for TNBC may be further modulated. For example, there is the opportunity to
de-escalate local treatment in case of good response (i.e., convert from mastectomy to conservative
surgery) or to escalate systemic treatment (i.e., further adjuvant chemotherapy or inclusion in adjuvant
clinical trials) for patients not achieving a pCR [6,7].
Triple-negative breast cancer represents the vast majority of BRCA1-related BCs (67.5%), whereas
about 7.5% of BRCA2-related BCs are TNBCs [8,9]. Even if the majority of all TNBCs arise in
the absence of a BRCA germline mutation, these tumors often present features of DNA repair
deficiency. These considerations have led to hypothesize that TNBC may be particularly susceptible to
DNA-damaging agents [1]. Platinum-containing NACT have been tested in TNBC with the aim to
increase the proportion of patients achieving a pCR and ultimately to improve long-term outcome,
leading to mixed results [10,11]. Current recommendations and statements in main international
guidelines are controversial:
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• National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines, version 1.2019 [12]:
“ . . . the NCCN panel does not recommend addition of carboplatin to neoadjuvant standard
chemotherapy for patients with triple-negative breast cancer outside a clinical trial setting”;
• Early breast cancer: European Society of Medical Oncology (ESMO) Clinical Practice Guidelines
for diagnosis, treatment and follow up (2019) [13]: “The addition of a platinum compound may
be considered in triple-negative tumors and/or in patients with deleterious BRCA1/2 mutations
[I, C]” (statement related to neoadjuvant chemotherapy);
• St. Gallen Consensus Conference 2017 [14]: “The Panel clearly recommended against routine use
of platinum-based chemotherapy in unselected TNBC cases. In BRCA1/2 associated cancers, the
Panel was evenly split on whether to recommend (neo)adjuvant platinum chemotherapy though
agreed that such patients should receive alkylating chemotherapy in addition to a taxane and
anthracycline”;
• European School of Oncology (ESO)—ESMO consensus guidelines for BC in young women
(BCY3) [15]: “In patients with TNBC or BRCA-associated tumors the incorporation of platinum
agents increases pCR rates and may be considered when neoadjuvant chemotherapy is indicated.
Data on the impact of incremental increases in pCR on long term outcome are not conclusive.
The use of platinum derivatives has potential additional impact on fertility and increased toxicity
that may compromise standard duration and dosing of systemic treatment, and this needs to be
clearly communicated to patients”, Level of Evidence IIA (weak recommendation, high-quality
evidence), 77% consensus.
None of these recommendations were developed with the Grades of Recommendation, Assessment,
Development, and Evaluation (GRADE) approach [16].
The panel of the Italian Association of Medical Oncology (AIOM) Guidelines on Breast Cancer
decided to develop in 2018 a clinical recommendation by applying the GRADE approach to address
the clinical question related to the inclusion of platinum in NACT for TNBC.
2. Results
2.1. Search Strategy Results and Details of the Identified Relevant Studies
The literature search returned 820 records. Of the 17 full-text articles assessed for eligibility,
5 studies [17–21] met the eligibility criteria (Figure 1, Table 1).
The BrighTNess study is a phase III randomized trial that randomized patients with TNBC
(estrogen and progesterone receptor <1% and HER2 negative) to receive: paclitaxel + carboplatin
+ veliparib followed by doxorubicin and cyclophosphamide; paclitaxel + carboplatin + veliparib
placebo followed by doxorubicin and cyclophosphamide; paclitaxel + carboplatin placebo + veliparib
placebo followed by doxorubicin and cyclophosphamide [17]. Eligibility criteria included: stage II–III
disease and documented germline BRCA test available. The primary endpoint was pCR (ypT0/is ypN0;
assessed by local pathologist), secondary endpoints included event-free survival, overall survival, and
breast-conserving surgery. For the primary endpoint analysis, the prespecified pairwise comparisons
were: paclitaxel + carboplatin + veliparib versus paclitaxel + carboplatin and paclitaxel + carboplatin
+ veliparib versus paclitaxel. Between 2014 and 2016, a total of n = 634 patients were randomized
(2:1:1; n = 316 paclitaxel + carboplatin + veliparib; n = 160 paclitaxel + carboplatin; n = 158 paclitaxel).
Randomization was stratified according to germline BRCA mutation, nodal stage (N0 versus N1–2)
and planned schedule of doxorubicin and cyclophosphamide (every 2 or 3 weeks). The population
included: 50% of patients aged ≤ 50 years, 15% of patients with a BRCA mutation, 83% of patients
with T1 or T2, 58% of patients with clinical node negative stage. For 55%, the planned schedule of
doxorubicin and cyclophosphamide administration was every 2 weeks.
The CALGB 40603 is a phase II study that enrolled 443 patients with stage II or III non-inflammatory
TNBC (estrogen and progesterone receptor ≤ 10% and HER2 negative) [18]. Patients received paclitaxel
followed by dose-dense doxorubicin + cyclophosphamide. Patients were randomized in a 2 × 2
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design to receive in addition carboplatin and/or bevacizumab (10 mg/kg every 2 weeks for 9 courses
concurrently to paclitaxel and the first 3 cycles of doxorubicin and cyclophosphamide). Randomization
was stratified by stage (II or III). The primary endpoint was pCR in the breast (ypT0/is, assessed by
local pathology). Two separate pairwise comparisons were planned: carboplatin (+/− bevacizumab)
versus no carboplatin (+/− bevacizumab) and bevacizumab (+/− carboplatin) versus no bevacizumab
(+/− carboplatin). Secondary endpoints included: pCR in breast and axilla (ypT0/is ypN0), treatment
delivery, treatment-related toxicities, residual cancer burden, conversion from node-positive to
pathologically node-negative status, conversion to breast-conserving surgery. Patients were also
monitored for relapse-free survival, time to first failure and overall survival. From 2009 to 2012,
454 patients were enrolled: 60% aged 40–59 years, 68% clinical stage II, 42% N0.
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Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart.
Table 1. Main characteristics of the studies considered for the GRADE assessment of the clinical question.
Study Name Phase nTNBC Treatment Arms
BrighTNess [15] * III 338
P 80 mg/mq qw for 12 w + Cb AUC 6 q3w for 4 courses→ AC (60
mg/mq and 600 mg/mq) q3w for 4 courses
P 80 mg/mq qw for 12 w + Cb AUC 6 q3w for 4 courses→ AC (60
mg/mq and 600 mg/mq) q3w for 4 courses
CALGB 40603 [16]
§ II 454
P 80 mg/mq qw for 12 w + Cb AUC6 q3w for 4 courses +/− Bev 10
mg/kg q2w for 9 courses◦ → ddAC (60 mg/mq and 600 mg/mq q2w
for 4 courses, with myeloid growth factor support)
P 80 mg/mq qw for 12 w +/− Bev 10 mg/kg q2w for 9 courses◦ →
ddAC (60 mg/mq and 600 mg/mq q2w for 4 courses, with myeloid
growth factor support)
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Table 1. Cont.
GeparSixto GBG66
[17] ˆ II 315
P 80 mg/mq qw + nplD 220 mg/mq qw + Bev 15 mg/kg q3w + Cb
AUC 2.0 or 1.5 qw for 18 w
P 80 mg/mq qw + nplD 220 mg/mq qw + Bev 15 mg/kg q3w for 18 w
GEICAM/2006-3
[18] II 93
EC (90 mg/mq and 600 mg/mq q3w for 4 courses)→ Doc 75 mg/mq
q3w for 4 courses + Cb AUC6 q3w for 4 courses
EC (90 mg/mq and 600 mg/mq q3w for 4 courses)→ Doc 100 mg/mq
q3w for 4 courses
UMIN000003355
[19] ˆ II 75
P 80 mg/mq qw for 12 w + Cb AUC5 q3w for 4 courses→ CEF (500
mg/mq, 100 mg/mq and 500 mg/mq) q3w for 4 courses
P 80 mg/mq qw for 12 w→ CEF (500 mg/mq, 100 mg/mq and 500
mg/mq) q3w for 4 courses
Abbreviations: n, number; TNBC, triple negative breast cancer; P, paclitaxel; Cb, carboplatin; AC, doxorubicin and
cyclophosphamide; Bev, bevacizumab; dd, dose dense; nplD, non-pegylated liposomal doxorubicin; EC, epirubicin
and cyclophosphamide; Doc, docetaxel; mq, square meter; AUC, area under the curve; qw, every week; w, week;
q3w, every 3 weeks; * Arm with veliparib not considered; § For the analysis of the outcomes of harm only treatment
arms not containing bevacizumab were considered; ◦ Bevacizumab was administered concurrently to paclitaxel and
the first 3 courses of doxorubicin/cyclophosphamide; ˆ For the analysis of the outcomes of harm, data in the entire
patient population (included non-TNBC) were considered.
The GeparSixto phase II randomized trial compared the following neoadjuvant treatments:
paclitaxel + non-pegylated liposomal doxorubicin (versus the same regimen combined with concomitant
carboplatin [19]. Patients diagnosed with TNBC (estrogen and progesterone receptor <1% and HER2
negative) or HER2-positive BC were eligible. Triple negative breast cancer patients also received
concomitant bevacizumab 15 mg/kg every 3 weeks; HER2-positive patients also received concomitant
trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) and lapatinib (750 mg daily).
Patients were eligible if they had clinical stage T2 to T4a–d tumors or T1c tumors with clinical or
histological node-positive disease. The randomization (1:1) was stratified by: biological subtype
(TNBC, HER2-positive/hormone receptor-negative, HER2-positive/hormone receptor positive) and
Ki67 level (≤20% or >20%). The primary endpoint was pCR (ypT0/ypN0) assessed by local pathologist
(pathology reports reviewed by an independent pathologist). Secondary outcomes were: tolerability,
treatment adherence, clinical/radiological response rates, pathological stages ypT0/is ypN0, ypT0/is
ypN0/+, and any ypT ypN0, regression grade, rate of breast, and axilla conservation. Efficacy was
assessed in pre-defined subgroups according to central triple-negative and HER2-positive subtypes
and Ki67 levels. From 2011 and 2012, 588 patients were enrolled (n = 293 without carboplatin, n = 295
with carboplatin): the majority had cT2 stage (64%) or cN0 stage (53%) by ultrasonography, n = 315
patients had TNBC.
The GEICAM/2006-03 phase II study enrolled patients from 2007 to 2010. Key eligibility criteria
were: basal-like BC (estrogen and progesterone receptor < 1%, HER2-negative, cytokeratin 5/6 or
epidermal growth factor receptor positive by immunohistochemistry), tumor size > 2 cm or <2 cm
with nodal involvement [20]. Patients were randomized 1:1 to receive: epirubicin + cyclophosphamide
followed by docetaxel or to epirubicin + cyclophosphamide followed by docetaxel + carboplatin.
Randomization was stratified according to institution, tumor size, histological tumor grade, and
axillary status. The primary endpoint was pCR in the breast. Secondary endpoints were: safety, clinical
response, breast conservative surgery, and axillary node status at the time of surgery. Although not
formally included as a study endpoint, the authors have also reported pCR in breast and axilla. A total
of 94 patients were enrolled: n = 46 received treatment without platinum, n = 47 received treatment
with platinum, n = 1 never started treatment. Median age was 47 years, 69% of patients had cT2 stage
and 48% were node-negative at baseline.
The UMIN000003355 study is a phase II randomized trial for patients with HER2-negative BC [21].
Patients were eligible if they had a tumor larger than 2 cm or a smaller tumor with clinically positive
axillary nodes (stages II-IIIA). Patients with T4 or N3 were excluded. Between 2010 and 2011, a total of
181 patients entered the study, two of which refused to undergo treatment. Patients were randomized
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to receive paclitaxel 80 mg/mq weekly for 12 weeks followed by cyclophosphamide + epirubicin +
5-fluorouracil (500 mg/mq, 100 mg/mq, 500 mg/mq every 3 weeks for 4 courses) or to the same regimen
with the addition of Carboplatin AUC 5 every 3 weeks for 4 courses administered concomitantly
to paclitaxel. Randomization was balanced for stage (II versus IIIA), hormone receptor status and
institution. The primary endpoint was pCR (ypT0/is ypN0), evaluated by central pathology. Secondary
endpoints were: disease-free survival, clinical response rate, breast conservation rate, safety. Median
age in the intention-to-treat population was 47 years, 82% of patients had stage II disease, 35% had node
negative status, 42% were triple negative (n = 75; n = 37 with carboplatin, n = 38 without carboplatin).
2.2. Outcomes of Benefit
Table 2 reports a summary of certainty of evidence assessment, absolute and relative effects
(evidence profile table).
2.2.1. pCR (ypT0/is ypN0)
All the five identified studies reported pCR rates [17–21]. For GeparSixto [19] and
UMIN000003355 [21] studies, only data for TNBC patients were considered. With regards to the CALGB
40603 study, data from the carboplatin arms (+/− bevacizumab) and the no-carboplatin arms (+/−
bevacizumab) were included, in accordance with the 2 × 2 design [18]. The results of the paclitaxel +
carboplatin + veliparib placebo and the paclitaxel + carboplatin placebo + veliparib placebo arms were
considered for the BrighTNess study, in order to avoid potential confounding effect of veliparib [17].
The certainty of evidence was judged as “low” due to the possible detection bias (lack of blinded
outcome assessor in most of the studies, with the exception of BrighTNess) and results heterogeneity
(I-squared = 55%). Overall, the probability of pCR was of 54 in every 100 patients in the platinum-based
chemotherapy group and 38 in the control group (RR = 1.45, 95%CI 1.28–1.64).
2.2.2. DFS/EFS and OS
Four studies included DFS/EFS as secondary endpoint [17–19,21], but only two reported survival
data: CALGB 40603 [22] and GeparSixto [23,24] (TNBC subgroup considered). The certainty of evidence
was judged as “very low” for DFS/EFS for the following reasons: heterogeneity (I-squared = 63.9%)
and imprecision (low number of events). Moreover, a possible publication bias was detected. Indeed,
both the BrighTNess [17] and the UMIN0000035 [21] trials had DFS/EFS has secondary endpoints but
have not reported data yet. With regards to BrighTNess, the follow-up period may be too short to
conduct such type of analysis; therefore, no publication bias was suspected. On the other hand, seven
years have lasted since the last patient enrollment in the UMIN000003355 trial, but survival data have
never been reported. No significant difference was observed for the comparison of platinum versus
non-platinum containing regimens (HR = 0.72, 95%CI 0.49–1.06).
Three studies included OS as secondary endpoint [17–19], but only two reported survival data:
CALGB 40603 [22] and Geparsixto [23,24] (TNBC subgroup considered). The certainty of evidence
was judged as “low” for OS for the following reasons: lack of blinding in GeparSixto, heterogeneity
(I-squared = 33%), and imprecision (low number of events). No publication bias was suspected for
BrighTNess since the follow-up period was probably too short to report OS analysis. No significant OS
difference was observed for the comparison of platinum vs. non-platinum containing regimens (HR =
0.86, 95%CI 0.46–1.63).
2.3. Outcomes of Harm
Table 2 reports a summary of certainty of evidence assessment, absolute and relative effects
(evidence profile table).
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Table 2. Evidence profile table for GRADE assessment. Question: In patients with triple-negative breast cancer who are candidates to receive neoadjuvant
chemotherapy, is the addition of a platinum agent to a taxane and anthracycline-containing regimen recommended versus a taxane and anthracycline-containing
regimen only? Setting: inpatients. Bibliography: BrighTness [15], CALGB 40603 Alliance [16,20], GeparSixto GBG66 [17,21,22], GEICAM/2006-03 [18], and
UMIN000003355 [19].
Certainty Assessment No of Patients Effect
Certainty Importance№ of
studies
Study
Design
Risk of
Bias Inconsistency Indirectness Imprecision
Other
Considerations
Platinum Added to
Taxane- and
Anthracycline-Based
Neoadjuvant
Chemotherapy
Taxane- and
Anthracycline-Based
Neoadjuvant
Chemotherapy only
Relative
(95% CI)
Absolute
(95% CI)
Overall survival (follow up: range 39 months to 47.3 months)
3 a randomisedtrials
not
serious serious
b not serious serious c none d 33/384 (8.6%) e 36/385 (9.4%) e
HR 0.86
(0.46 to
1.63)
1 fewer per
100
(from 5
fewer to 5
more)
⊕⊕#
LOW
CRITICAL
DFS/EFS (follow up: range 39 months to 47.3 months)
4 f
randomised
trials serious
g serious h not serious serious i
publication
bias
STRONGLY
suspected j
75/384 (19.5%) e 100/385 (26.0%) e
HR 0.72
(0.49 to
1.06)
7 fewer per
100
(from 12
fewer to 1
more)
⊕###
VERY
LOW
CRITICAL
Pathological complete response rate (assessed with: no residual invasive tumour in both the breast and the axilla: i.e., ypT0/is pN0)
5 k
randomised
trials serious
l serious m not serious not serious none 338/623 (54.3%) e 229/611 (37.5%) e
RR 1.45
(1.28 to
1.64)
17 more per
100
(from 10
more to 24
more)
⊕⊕##
LOW
CRITICAL
Febrile neutropenia
5 k
randomised
trials
not
serious not serious
not serious
n,o serious i none 63/701 (9.0%) 44/695 (6.3%)
RR 1.42
(0.98 to
2.06)
3 more per
100
(from 0
fewer to 7
more)
⊕⊕⊕#
MODERATE
CRITICAL
Anemia grade 3/4
5 k
randomised
trials
not
serious not serious
not serious
n,o serious i none 99/701 (14.1%) 2/695 (0.3%)
RR 49.08
(12.15 to
198.20)
14 more per
100
(from 3
more to 57
more)
⊕⊕⊕#
MODERATE
IMPORTANT
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Table 2. Cont.
Certainty Assessment No of Patients Effect
Certainty Importance№ of
studies
Study
Design
Risk of
Bias Inconsistency Indirectness Imprecision
Other
Considerations
Platinum Added to
Taxane- and
Anthracycline-Based
Neoadjuvant
Chemotherapy
Taxane- and
Anthracycline-Based
Neoadjuvant
Chemotherapy only
Relative
(95% CI)
Absolute
(95% CI)
Seriuos adverse events
3 p randomisedtrials serious
q not serious r not seriousn,o not serious none 174/566 (30.7%) 134/558 (24.0%)
RR 1.28
(1.06 to
1.55)
7 more per
100
(from 1
more to 13
more)
⊕⊕⊕#
MODERATE
CRITICAL
Thrombocytopenia grade 3/4
5 k
randomised
trials
not
serious not serious
s not serious
n,o serious i none 79/701 (11.3%) 5/695 (0.8%)
RR 15.66
(6.38 to
38.44)
11 more per
100
(from 4
more to 27
more)
⊕⊕⊕#
MODERATE
IMPORTANT
CI: confidence interval; HR: hazard ratio; RR: risk ratio; Explanations: a. CALGB 40603 Alliance, GeparSixto GBG66 and BrighTness. b. I-squared = 63.9%. c. Downgraded for imprecision
due to the small number of events. d. Only two reported survival analysis. OS was a secondary endpoint for BrighTNess, but data have not been reported yet. Follow-up was probably too
short for survival analysis; therefore, no publication bias was suspected. e. CALGB 40603 Alliance: intention-to-treat population considered (all randomized). f. CALGB 40603 Alliance,
GeparSixto GBG66, UMIN000003355 and BrighTNess. g. Possible detection bias due to the lack of masking in GeparSixto. h. I-squared = 33%. i. Downgraded for imprecision due to
the small number of events. j. UMIN000003355 and BrighTNess studies stated as secondary outcome DFS/EFS but did not report data. Follow-up was probably too short for survival
analysis; therefore, no publication bias was suspected. Instead, follow up in UMIN000003355 may be mature for survival analysis, therefore, a publication bias was suspected. k. CALGB
40603 Alliance, GeparSixto GBG66, BrighTness, GEICAM/2006-03 and UMIN000003355. l. Possible detection bias due to the lack of blinded outcome assessor. m. I-squared = 55%. n.
For BrighTNess study, safety data occurring during the first segment of neoadjuvant chemotherapy were considered. o. UMIN000003355 and GeparSixto studies reported in the entire
study population, including non-TNBC. HER2-positive patients in GeparSixto GBG66 also received trastuzumab and lapatinib. p. GeparSixto GBG66, BrighTness and CALGB 40603
Alliance. q. Possible detection bias due to the lack of masking in CALGB 40603 and GeparSixto GBG66 studies. r. I-squared = 26%, s. I-squared = 16%.
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All five studies reported data for febrile neutropenia (critical), thrombocytopenia G3–4 (important)
and anemia G3–4 (important) [17–21]. Three studies [17–19] (BrighTNess, CALGB40603 and GeparSixto)
reported the rate of serious adverse events (critical).
For CALGB 40603 study, only the arms without bevacizumab were considered, since the addition
of the antiangiogenic drug had some effect on safety [18].
From the BrighTNess trial, safety data of the paclitaxel + carboplatin + veliparib placebo
and paclitaxel + carboplatin placebo + veliparib placebo were considered, in order to avoid
potential confounding from the administration of veliparib [17]. The authors of the BrighTNess
study reported the safety data separately for the first and second segments of therapy (taxane-based
and doxorubicin/cyclophosphamide, respectively) [17], and it was not possible to extrapolate from the
publication the overall rate of specific adverse events occurring in the entire treatment period since the
same patients might have experienced the same event in the first and second segment. The panel opted
to consider in the evidence profile table the events occurring in the first segment, but also discussed the
rate of events described for the second segment and took into consideration in the assessment process.
This was based on the assumption that the previous exposure to taxane-based regimens with potentially
different toxicity profile could influence the tolerability of subsequent anthracycline chemotherapy.
In the GeparSixto [19] and UMIN00000335 [21] trials, safety data were reported for the entire
population of patients and not according to tumor biology. However, the results of these trials were
included in the analysis, assuming that HER2 and/or hormone receptor status should have no effect
on safety.
2.3.1. Febrile Neutropenia
The certainty of evidence was judged as “moderate” due to the imprecision (low number of
events). Neoadjuvant treatment regimens containing platinum resulted in a non-significant increase in
the risk of febrile neutropenia: 9% versus 6.3%, RR = 1.42 (95%CI 0.98–2.06).
In the BrighTNess study, 26 patients treated with carboplatin and 7 treated without carboplatin
experienced a febrile neutropenia in the second segment of study treatment (16.5% and 4.5%) [17].
2.3.2. Serious Adverse Events
The certainty of evidence was judged as “moderate” due to the lack of masking in the CALGB
40,603 trial. The addition of platinum to an anthracycline and taxane-based chemotherapy regimen
resulted in significantly higher rate of serious adverse events: 30.7% versus 24.0%, RR = 1.28 (95%CI
1.06–1.55).
In the BrighTNess study, 32 and 16 SAEs were reported in the second treatment segment for
patients treated with carboplatin and patients not treated with carboplatin (20.3% and 10.2%) [17].
2.3.3. Anemia G3–G4
The certainty of evidence was judged as “moderate” due to the imprecision (low number of
events). Neoadjuvant treatment regimens containing platinum resulted in a significantly higher risk of
G3–G4 anemia: 14.1% versus 0.3%, RR = 49.08 (95%CI 12.15–198.20).
In the BrighTNess study, 36 patients treated with carboplatin and 12 treated without carboplatin
experienced G3–G4 anemia in the second segment of study treatment (22.8% and 7.6%) [17].
2.3.4. Thrombocytopenia G3–G4
The certainty of evidence was judged as “moderate” due to the imprecision (low number of
events). The addition to platinum to an anthracycline and taxane-based chemotherapy regimen
resulted in significantly higher risk of G3–G4 thrombocytopenia: 11.3% versus 0.8%, RR = 15.66 (95%CI
6.38–38.44).
In the BrighTNess study, 10 patients treated with carboplatin and two treated without carboplatin
experienced a G3–G4 thrombocytopenia in the second segment of study treatment (6.3% and 1.3%) [17].
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2.4. EtD (Evidence to Decision) Framework
The full EtD table is reported in Table 2.
In summary, the panel judged the problem addressed by the clinical question as a priority, by
acknowledging the unmet clinical need of improving the outcome for TNBC, the strong prognostic
value of pCR.
The panel acknowledged the absence of a clear positive impact on survival by the addition of
platinum. However, the observed difference in pCR favoring the addition of a platinum agent was
considered sufficient to judge as “moderate” the substantiality of the desirable anticipated effects.
The panel considered in this evaluation the lack of power of neoadjuvant studies to detect significant
survival differences.
The panel judged as “small” the substantiality of undesirable effects. In their appraisal, panel
members stated that the heterogeneity of treatment schedules across the studies [17–21] might have
partly influenced the rate of the undesirable effects, making an overall judgement more complex.
In particular, the panel noted that in most of the studies carboplatin was administered every 3 weeks,
whereas, based on panel members’ opinion and experience, the most manageable schedule is carboplatin
AUC every 2 weeks.
The certainty of evidence was described as very low since most outcomes were affected by
inconsistency and imprecision of estimates.
2.5. Benefit/Harm Balance and Final Recommendation
The panel voted for the benefit/harm benefit as uncertain–favorable (10 votes out of 11 members).
The strength of the recommendation was voted as conditionally positive by 10 out of 11 panel members.
Hence, the final recommendation released by the panel was:
“In patients with triple-negative breast cancer who are candidates to receive neoadjuvant
chemotherapy, the addition of platinum to a standard regimen containing anthracycline and
taxane may be taken into consideration”.
The final recommendation and summary of the GRADE evaluation is reported in Table 3.
Table 3. Final recommendation and summary of GRADE evaluation.
CLINICAL QUESTION: In patients with triple-negative breast cancer who were to receive neoadjuvant
chemotherapy, was the addition of a platinum agent to a taxane and anthracycline-containing regimen
recommendable versus a taxane and anthracycline-containing regimen only?
Recommendation: In patients with triple-negative breast cancer, receiving neoadjuvant chemotherapy, the
addition of platinum to a standard regimen containing anthracycline and taxane may be taken into
consideration
Strength of recommendation: CONDITIONAL POSITIVE
Quality of evidence: Outcomes of benefit: Very Low; Outcomes of harm: Moderate
Reasons/comments on the benefit/harm balance
Outcomes of benefit. The Panel identified as “critical” the following outcomes of benefit: pCR, DFS/EFS and
OS. Five randomized controlled trials (RCTs) with the same anthracycline and taxane-based chemotherapy
backbone in the platinum (carboplatin) and no-platinum arms were considered for the assessment of the
clinical question [17–21] All five studies reported pCR [17–21] and only two studies reported survival data
[18,19,22–24]. The risk of pCR was 54 every 100 patients with carboplatin and 37 every 100 patients without
carboplatin (RR 1.45, 95% CI 1.28–1.64). The quality of evidence in support of pCR outcome was low (potential
bias due to the possible lack of blinded outcome assessor and heterogeneity with I-squared 55%). There was no
significant difference in favor of the addition of platinum for: DFS/EFS (HR 0.72, 95% CI 0.49–1.06) and OS (HR
0.86, 95%CI 0.46–1.63). Although the available evidence was insufficient to detect a significant difference in
survival (low number of events and short follow-up), considering the difference in pCR, the panel judged as
“moderate” the substantiality of the desirable effects derived from the addition of platinum to anthracycline
and taxane-based neoadjuvant chemotherapy.
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Table 3. Cont.
Reasons/comments on the benefit/harm balance
Outcomes of harm. The Panel identified the following outcomes of harms: febrile neutropenia, anemia (grade
3–4), serious adverse event (SAE), thrombocytopenia (grade 3–4). Only febrile neutropenia and SAE were
considered “critical outcomes”. The addition of platinum to a standard anthracycline and taxane-based
chemotherapy was not associated with a significant difference in the risk of febrile neutropenia (RR 1.42, 95%
CI 0.98 to 2.06). The addition of platinum significantly increased the risk of SAE (RR 1.28, 95% CI 1.06 to 1.55),
grade 3–4 anemia (RR 49.08, 95% CI 12.15 to 198.20), and grade 3–4 thrombocytopenia (RR 15.66, 95% CI 6.38 to
38.44). The panel also considered the adverse events occurring in the BrighTNess study in the second treatment
segment (anthracycline-based) that were not included in the overall assessment. The Panel, considering the
heterogeneity of treatment schedules applied in the different studies that might have influenced the incidence
of adverse events, judged as “small” the substantiality of the undesirable effects. Although the survival impact
of the addition of platinum remains undefined, the Panel voted for the benefit/harm balance as
uncertain-favorable, considering the increase in pCR rates and the acceptable safety costs.
Vote on benefit/harm balance
Favorable Uncertain (Favorable) Uncertain(Unfavorable) Unfavorable
10 1
Vote on strength of recommendation
Strong Positive Weak Positive Weak Negative Strong Negative
10 1
Implications for future research: a longer follow-up of those studies that report DFS/EFS and/or OS as
secondary endpoint is necessary in order to define the survival impact of the addition of platinum.
3. Discussion
The AIOM Clinical Practice Guidelines on Breast Cancer panel suggests the addition of platinum
to an anthracycline and taxane neoadjuvant regimen as an option that may be taken into consideration
for TNBC patients. This recommendation derived from a critical appraisal of available evidence
through a rigorous methodology and discussion, as highlighted in this paper.
Of the outcomes of benefit, only pCR rate was significantly improved with the addition of
platinum, with an absolute increase of 17%. Although there was no clear benefit in survival outcomes
and the analysis of harms showed a significant increase in the rate of SAEs, G3–G4 anemia and
thrombocytopenia and a numerical increase in febrile neutropenia, the overall recommendation
was conditional in favor of the intervention. The appraisal that led to this recommendation has been
described in details in this paper. The final recommendation highlights the relevance that was attributed
by the panel to the effect on pCR, which has the strongest association with long-term outcome in the
challenging and hard-to-treat TNBC subtype. However, it remains unclear whether platinum use
in neoadjuvant setting could also improve long-term survival, more data and longer follow up are
needed. Moreover, a deeper understanding of molecular heterogeneity of TNBC and how it may guide
treatment choice represent a research priority [25,26]. Some additional specific issues may deserve
some further discussion.
The clinical question and the related recommendation were not restricted to BRCA mutation
carriers only, but involved all unselected TNBC patients. In the metastatic setting, there is evidence
from a randomized phase III trial that carboplatin is more effective than docetaxel as first line therapy
for TNBC patients only in the subgroup with a germline BRCA mutation [27]. Although it was initially
suggested that the benefit of neoadjuvant platinum agents could be restricted to BRCA carriers [28,29],
this issue remains controversial [23]. Indeed, data from a recent meta-analysis suggest no differential
benefit from platinum-based NACT according to BRCA status: pCR rates were 58.0% with platinum
and 54.3% without platinum in BRCA-mutated patients and 57.0% with platinum and 32.7% without
platinum in BRCA-wilde type patients [11]. Another meta-analysis compared the pCR rates after
neoadjuvant chemotherapy with platinum compounds for BRCA-mutated versus non-BRCA-mutated
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TNBC patients: although the pCR rate was numerically higher for BRCA-mutated cases (58.4% versus
50.7%), the difference was not statistically significant [30]. These data may indeed highlight a higher
general chemosensitivity of BRCA-mutated patients [31].
Alkylating agents are other fundamental drugs for TNBC, due to the mechanism of action [32,33].
In the clinical question developed by the AIOM panel, the treatment of reference is an anthracycline
and taxane-containing regimen. All the studies included in the evaluation of the clinical question
also included cyclophosphamide in the chemotherapy backbone [17,18,20,21], with the exception
of GeparSixto [19]. This difference, together with other sources of treatment heterogeneity across
studies, might have influenced the evaluation of the effects of the addition of platinum. It has to be
specified that all the anthracycline and taxane-based adjuvant/neoadjuvant regimens listed in the
AIOM Clinical Practice Guidelines on Breast Cancer [34] also contain cyclophosphamide. Therefore,
the AIOM recommendation should be interpreted within this frame.
The selection of the outcome of harms highlighted a particular concern about hematologic toxicity,
which is a typical set of adverse events related to platinum agents. Peripheral neuropathy, which is
also specifically related to platinum [35], was not considered as a relevant outcome of harm. The panel
commented that potential neurotoxic combinations of platinum and taxanes are already widely used in
other diseases in clinical practice, with known toxicity rates. What was unique to this clinical question
was the addition of platinum to a regimen containing both taxane and anthracycline, raising a major
concern for myeloid suppression. Moreover, a recent meta-analysis reported low and similar rates
of grade 3–4 neuropathy in platinum-containing and platinum-free neoadjuvant regimens for TNBC
(3.6% in both groups) [11].
4. Materials and Methods
4.1. The AIOM Guidelines on Breast Cancer Panel
The AIOM Guidelines on Breast Cancer are updated every year by a panel composed of academics
and clinicians with expertise in medical oncology, surgery, radiation therapy, pathology, radiology, and
clinical research methodology. The draft of the updated guidelines is sent to external reviewers prior
to the final publication on the AIOM website [34]. The external reviewers are nominated by AIOM and
other relevant scientific societies (for 2018: Italian National Association of Breast Surgeons (ANISC),
Italian Society of Anatomic Pathology and Diagnostic Cytopathology (SIAPEC), Italian Society of
Radiation Oncology (AIRO)).
4.2. Development of Clinical Question
The clinical question was developed according to the P.I.C.O. acronym requiring the definition of:
population (P), intervention (I), comparison (C), and outcomes (O).
For the 2018 version of the AIOM Guidelines on Breast Cancer, the panel decided to address the
following clinical question:
• In patients with triple-negative breast cancer candidate to receive neoadjuvant chemotherapy, is the
addition of a platinum agent to a taxane and anthracycline-containing regimen recommendable
versus a taxane and anthracycline-containing regimen only?
The panel defined, as population of interest, unselected TNBC patient candidates to receive
NACT without restricting to BRCA-carriers only, consistently with the approach followed by other
BC guidelines. The panel considered in the clinical question an anthracycline and taxane-containing
regimen as the standard reference chemotherapy, since this is the preferred treatment recommended
by AIOM and other BC guidelines for TNBC [12–14]. Therefore, the intervention is the addition of
platinum to a regimen already containing anthracycline and taxane.
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4.3. Identification of Outcomes
The panel identified the following outcomes of benefit: pCR rate (absence of residual invasive
cancer cells in both breast and axilla, ypT0/is ypN0), disease/event-free survival (DFS/EFS), and overall
survival (OS). All these outcomes were judged as “critical” for the decision-making.
The panel identified the following outcomes of harm: febrile neutropenia, anemia (grade 3–4),
thrombocytopenia (grade 3–4), serious adverse events (SAEs). Febrile neutropenia and SAEs were
judged as “critical”, the other outcomes as “important”.
4.4. Search Strategy and Selection of Evidence
A systematic literature search was performed searching PubMed, Embase and Cochrane Library
without date restriction up to May 2018. The full search strategy is available in Appendix A. Main
articles were cross-referenced to check that all the relevant literature was fully identified. The PRISMA
flow-chart is reported in Figure 1. Retrospective or prospective non-randomized studies were excluded.
Studies that also enrolled non-TNBC patients were considered, provided that at least efficacy data in
the subgroup of TNBC were reported. Only those studies with the same anthracycline and taxane
chemotherapy backbone in both arms were eligible.
Information on study design characteristics of patients enrolled, treatment received and study
results were collected.
4.5. Quality of Evidence Evaluation
According to the GRADE approach, an evaluation of the certainty of evidence for each selected
outcome was performed. The GRADE evaluation encompasses five main domains: study limitations,
imprecision, indirectness, inconsistency and publication bias. Based on the study design, the certainty
level starts at a pre-specified level (high certainty for randomized controlled trials). The detection
of limitations in one or more of the five domains can lead to downgrading the certainty of evidence.
The final judgment can be one of the following: high, moderate, low and very low. A summary of
the certainty of evidence and a quantitative synthesis of the effects for each outcome are reported in a
dedicated evidence profile table.
4.6. Evidence to Decision (EtD) Framework
The EtD framework provides a transparent and structured approach to support the
decision-making process [36]. It allows to summarize the evidence in relation to the priority of
the problem, the substantiality of the desirable and undesirable effects, balance of the effects, certainty
of evidence, patients’ values and preference, use of resources, equity, acceptability, and feasibility.
4.7. Benefit/Harm Balance and Clinical Recommendation
The panel voted one of the following option for the balance between benefits and harms of
the intervention and the comparison: favorable, uncertain/favorable, uncertain/unfavorable, and
unfavorable. The panel also voted the strength of the recommendation according to the following
options: strong positive, conditional positive, conditional negative, strong negative.
The AGREE-reporting checklist was followed to guide the reporting of the recommendation [37].
5. Conclusions
In conclusion, with the available evidence, the AIOM panel defined the inclusion of platinum in
NACT for TNBC as an option. The strength of recommendation “conditional positive” indicates that
there is still a not-negligible uncertainty related to the effect of the intervention. Therefore, the individual
decision should be based on case-by-case clinical reasoning [38], balancing benefits, harms, and patient’s
preferences. Further follow-up might clarify the long-term impact of platinum-containing regimens.
Cancers 2019, 11, 1137 14 of 18
Author Contributions: All authors contributed to the development of the GRADE recommendation
(conceptualization, methodology, formal analysis). M.V.D., L.D.M., F.M., L.B., L.C., A.Z., C.C., A.L., B.C.,
M.C., A.F., C.M., C.T., and S.G. are members of the AIOM Guidelines on Breast Cancer 2018 panel. S.G. is the
coordinator of the AIOM Guidelines on Breast Cancer 2018. M.V.D. is the scientific secretary of AIOM Guidelines
on Breast Cancer 2018 panel. M.C., G.P., V.A.F. are members of the methodology group that supported the
panel members in the development of GRADE recommendation (methodology, formal analysis, data curation).
M.V.D., S.G., and M.C.: original draft preparation, supervision. All authors: review, editing, and approval of the
final manuscript.
Funding: This research received no external funding.
Conflicts of Interest: All potential conflicts of interests are outside the present work. Maria Vittoria Dieci has
received fees for consultancy and/or participation on advisory boards from Eli Lilly, Genomic Health, Celgene;
travel grants from Pfizer. Lucia Del Mastro has received honoraria, or fees for consultancy or travel grants from:
Roche, Novartis, Celgene, Genomic Health, Eisai, Ipsen, Takeda, MSD, Eli Lilly, Pfizer. Filippo Montemurro has
received travel grants from Roche; speaker’s honoraria from Roche, Novartis, Eli Lilly, Pfizer. Laura Biganzoli
has served as a consultant and in an advisory role for AstraZeneca, Celgene, Eisai, Genomic Health, Ipsen,
Lilly, Novartis, Pfizer, Pierre Fabre, Roche; has received research funding from Celgene, Genomic Health and
Novartis. Laura Cortesi has received honoraria from AstraZeneca, Pfizer, MSD, Novartis. Alberto Zambelli
has received honoraria from Novartis, Pfizer, Roche and AstraZeneca. Carmen Criscitiello has received fees for
speaker’s bureau and/or consultancy from Pfizer, Novartis, Eli Lilly and Roche. Caterina Marchiò has received
personal/consultancy fees from Bayer, Daiichi-Sankyo, Axiom Healthcare Strategies.
Appendix A Research Strategy
PubMed
((((((((((((((“Triple Negative Breast Neoplasms/drug therapy” [Mesh] OR “Triple Negative Breast
Neoplasms/pathology” [Mesh]))) OR (“triple negative breast Cancer” [Title/Abstract] OR “triple
negative breast neoplasms” [Title/Abstract] OR “triple negative breast tumo*” [Title/Abstract]))))))))
AND
((((((((((((((((“Platinum Compounds/therapeutic use” [Mesh]) OR ((((((((“Carboplatin” [Mesh]) OR
“Platinum” [Mesh])) OR (Cisplatinum [Text Word] OR carboplatinum [Text Word] OR Platinum [Text
Word] OR “platinum compound*” [Text Word] OR “platinum containing regime*” [Text Word] OR
biocisplatinum [Text Word] OR platino [Text Word] OR platinol [Text Word] OR paraplatin [Text
Word])) OR (((cisplatin [Text Word] OR oxilaplatin [Text Word] OR carboplatin [Text Word]))))))) OR
(“Neoadjuvant Therapy” [Mesh]) OR “Neoadjuvant Therapy” [Title/Abstract]))))))
AND
((((“Neoadjuvant Therapy” [Mesh]) OR “Neoadjuvant Therapy” [Title/Abstract])))))) OR
((“Anthracyclines” [Mesh]) OR (Anthracycline* [Text Word] OR Daunorubicin [Text Word] OR
Doxorubicin [Text Word] OR Idarubicin [Text Word] OR epirubicin [Text Word] OR valrubicin [Text
Word] OR Aclarubicin [Text Word] OR Carubicin [Text Word] OR Nogalamycin [Text Word] OR
Plicamycin [Text Word])))) AND
((((((“Neoadjuvant Therapy” [Mesh]) OR “Neoadjuvant Therapy” [Title/Abstract])))))))) OR ((“Taxoids”
[Mesh]) OR (Taxoids [Text Word] OR docetaxel [Text Word] OR paclitaxel [Text Word] OR nab-paclitaxel
[Text Word] OR Cabazitaxel [Text Word]))))
Embase
#1 ‘triple negative breast cancer’/exp OR ‘triple negative breast cancer’
#2 ‘triple negative breast cancer’ OR ‘triple negative breast neoplasms’ OR ‘triple negative breast
tumo*’:de,ti,ab
#3 #1 OR #2
#4 ‘platinum derivative’/exp OR ‘carboplatin’/exp
#5 cisplatinum OR carboplatinum OR platinum OR ‘platinum compound*’ OR ‘platinum containing
regime*’ OR biocisplatinum OR platino OR platinol OR paraplatin OR cisplatin OR oxilaplatin OR
carboplatin:de,ti,ab
Cancers 2019, 11, 1137 15 of 18
#6 #4 OR #5
#7 ‘neoadjuvant therapy’/exp
#8 ‘neoadjuvant therapy’:de,ti,ab
#9 #7 OR #8
#10 ‘anthracycline’/exp
#11 anthracycline* OR daunorubicin OR doxorubicin OR idarubicin OR epirubicin OR valrubicin OR
aclarubicin OR carubicin OR nogalamycin OR plicamycin:de,ti,ab
#12 #10 OR #11
#13 ‘taxoid’/exp
#14 taxoids OR docetaxel OR paclitaxel OR nab-paclitaxel OR cabazitaxel:de,ti,ab
#15 #13 OR #14
#16 #6 AND #12 AND #15
#17 #9 OR #16
#18 #3 AND #17
#19 ‘crossover procedure’:de OR ‘double-blind procedure’:de OR ‘randomized controlled trial’:de
OR ‘single-blind procedure’:de OR random*:de,ab,ti OR factorial*:de,ab,ti OR crossover*:de,ab,ti OR
((cross NEXT/1 over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl*
NEAR/1 blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti
#20 #18 AND #19
#21 #18 AND #19 AND ( [article]/lim OR [article in press]/lim) AND [embase]/lim
Cochrane
#1 MeSH descriptor: [Triple Negative Breast Neoplasms] explode all trees
#2 (‘triple negative breast cancer’ OR ‘triple negative breast neoplasms’ OR ‘triple negative breast
tumo*’):ti,ab,kw (Word variations have been searched)
#3 #30 OR #31
#4 MeSH descriptor: [Platinum Compounds] explode all trees
#5 MeSH descriptor: [Carboplatin] explode all trees
#6 (cisplatinum OR carboplatinum OR platinum OR ‘platinum compound*’ OR ‘platinum containing
regime*’ OR biocisplatinum OR platino OR platinol OR paraplatin OR cisplatin OR oxilaplatin OR
carboplatin):ti,ab,kw (Word variations have been searched)
#7 #33 OR #34 OR #35
#8 MeSH descriptor: [Anthracyclines] explode all trees
#9 (anthracycline* OR daunorubicin OR doxorubicin OR idarubicin OR epirubicin OR valrubicin
OR aclarubicin OR carubicin OR nogalamycin OR plicamycin):ti,ab,kw (Word variations have
been searched)
#10 #37 OR #38
#11 MeSH descriptor: [Taxoids] explode all trees
#12 (taxoids OR docetaxel OR paclitaxel OR nab-paclitaxel OR cabazitaxel):ti,ab,kw (Word variations
have been searched)
#13 #40 OR #41
#14 MeSH descriptor: [Neoadjuvant Therapy] explode all trees
#15 #36 AND #39 AND #42
#16 #44 OR #43
#17 #45 AND #32
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